Document Detail


Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.
MedLine Citation:
PMID:  18548000     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension in children.(1) ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and cardiac hypertrophic properties of angiotensin II and the vasodilatory and natriuretic properties of bradykinin; they also alter the metabolism of other vasoactive substances.(2) Through these mechanisms, ACE inhibitors decrease systemic vascular resistance and promote natriuresis without increasing heart rate. This study evaluated the results of six trials of ACE inhibitors in children, using meta-analytic techniques to estimate the effect of race on blood pressure response.
Authors:
J S Li; C M Baker-Smith; P B Smith; V Hasselblad; M D Murphy; R M Califf; D K Benjamin
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review     Date:  2008-06-11
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  84     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-08-20     Completed Date:  2008-09-02     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  315-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
African Continental Ancestry Group*
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Antihypertensive Agents / pharmacology*,  therapeutic use
Blood Pressure / drug effects*
Child
European Continental Ancestry Group*
Female
Humans
Hypertension / drug therapy
Male
Randomized Controlled Trials as Topic
Grant Support
ID/Acronym/Agency:
1U10-HD45962-04/HD/NICHD NIH HHS; 1UL1RR024128-01/RR/NCRR NIH HHS; U10 HD045962/HD/NICHD NIH HHS; U10 HD045962-04/HD/NICHD NIH HHS; UL1 RR024128-01/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents
Comments/Corrections
Erratum In:
Clin Pharmacol Ther. 2008 Nov;84(5):636

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Next Document:  The consequence of concomitantly present functional genetic variants for the identification of funct...